title: Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
abstract: OBJECTIVE
  This study evaluated changes in weight, glucose and lipid metabolism in patients with schizophrenia and antipsychotic-related metabolic disturbances who were switched to ziprasidone.
  
  
  METHODS
  Eighty-four outpatients with schizophrenia or schizoaffective disorder also having glucose intolerance, diabetes, dyslipidemia or weight gain related to their antipsychotic treatment were switched to ziprasidone. Clinical status was assessed using the Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I) scales and the Positive and Negative Syndrome Scale (PANSS). Assessment scales, weight, glucose and lipids were measured at baseline and at three and six months of ziprasidone treatment.
  
  
  RESULTS
  Significant baseline to endpoint reductions were seen in mean weight (-5.1 kg), Body Mass Index (BMI; -1.6 kg/m(2)), serum glucose (-14.0 mg/dL), total cholesterol (-24.1 mg/dL), and triglyceride leves (-46.2 mg/dL). Mean PANSS total score improved 13.9% after 6 months of treatment with ziprasidone. A proportion (34.3%) of patients were classified as much improved in the CGI-I.
  
  
  CONCLUSIONS
  Switching patients with schizophrenia to ziprasidone when metabolic disturbances are detected may improve these side effects and result in an improved overall outcome.
authors.affiliation: CSM Fuenlabrada, Avenida de la Comunidad de Madrid 10, Fuenlabrada 28945, Madrid, Spain. j_m_montes@hotmail.com
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Montes
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Rodriguez
authors.forename: Eduardo
authors.initials: E
authors.lastname: Balbo
authors.forename: Pedro
authors.initials: P
authors.lastname: Sopelana
authors.forename: Eloy
authors.initials: E
authors.lastname: Martin
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Soto
authors.forename: Jose Francisco
authors.initials: JF
authors.lastname: Delgado
authors.forename: Teresa
authors.initials: T
authors.lastname: Diez
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Villardaga
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D002784:Cholesterol